Exercise limitation in hypertrophic cardiomyopathy: combined stress echocardiography and cardiopulmonary exercise test.
Cardiopulmonary exercise test
Exercise intolerance
Hypertrophic cardiomyopathy
Stress echocardiography
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
18 Apr 2024
18 Apr 2024
Historique:
revised:
16
02
2024
received:
16
06
2023
accepted:
15
03
2024
medline:
19
4
2024
pubmed:
19
4
2024
entrez:
19
4
2024
Statut:
aheadofprint
Résumé
The study aims to investigate exercise-limiting factors in hypertrophic cardiomyopathy (HCM) using combined stress echocardiography and cardiopulmonary exercise test. A symptom-limited ramp bicycle exercise test was performed in the semi-supine position on a tilting dedicated ergometer. Echocardiographic images were obtained concurrently with gas exchange measurements along predefined stages of exercise. Oxygen extraction was calculated using the Fick equation at each activity level. Thirty-six HCM patients (mean age 67 ± 6 years, 72% men, 18 obstructive HCM) were compared with age and sex-matched 29 controls. At rest, compared with controls, E/E' ratio (6.26 ± 2.3 vs. 14 ± 2.5, P < 0.001) and systolic pulmonary artery pressures (SPAP) (22.6 ± 3.4 vs. 34 ± 6.2 mmHg, P = 0.023) were increased. Along with the stages of exercise (unloaded; anaerobic threshold; peak), diastolic function worsened (E/e' 8.9 ± 2.6 vs. 13.8 ± 3.6 P = 0.011; 9.4 ± 2.3 vs. 18.6 ± 3.3 P = 0.001; 8.7 ± 1.9 vs. 21.5 ± 4, P < 0.001), SPAP increased (23 ± 2.7 vs. 33 ± 4.4, P = 0.013; 26 ± 3.2 vs. 40 ± 2.9, P < 0.001; 26 ± 3.5 vs. 45 ± 7 mmHg, P < 0.001), and oxygen consumption (6.6 ± 1.7 vs. 6.8 ± 1.6, P = 0.86; 18.1 ± 2.2 vs. 14.6 ± 1.5, P = 0.008; 20.3 ± 3 vs. 15.1 ± 2.1 mL/kg/min, P = 0.01) was reduced. Oxygen pulse was blunted (6.3 ± 1.8 vs. 6.2 ± 1.9, P = 0.79; 10 ± 2.1 vs. 8.8 ± 1.6, P = 0.063; 12.2 ± 2 vs. 8.2 ± 2.3 mL/beat, P = 0.002) due to an insufficient increase in both stroke volume (92.3 ± 17 vs. 77.3 ± 14.5 P = 0.021; 101 ± 19.1 vs. 87.3 ± 15.7 P = 0.06; 96.5 ± 12.2 vs. 83.6 ± 16.1 mL, P = 0.034) and oxygen extraction (0.07 ± 0.03 vs. 0.07 ± 0.02, P = 0.47; 0.13 ± 0.02 vs. 0.10 ± 0.03, P = 0.013; 0.13 ± 0.03 vs. 0.11 ± 0.03, P = 0.03). Diastolic dysfunction, elevated SPAP, and the presence of atrial fibrillation were associated with reduced exercise capacity. Both central and peripheral cardiovascular limitations are involved in exercise intolerance in HCM. Diastolic dysfunction seems to be the main driver for this limitation.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol 2020;76:e159‐e240. doi:10.1016/j.jacc.2020.08.045
Chikamori T, Counihan PJ, Doi YL, Takata J, Stewart JT, Frenneaux MP, et al. Mechanisms of exercise limitation in hypertrophic cardiomyopathy. J Am Coll Cardiol 1992;19:507‐512. doi:10.1016/S0735‐1097(10)80262‐1
Le VV, Perez MV, Wheeler MT, Myers J, Schnittger I, Ashley EA. Mechanisms of exercise intolerance in patients with hypertrophic cardiomyopathy. Am Heart J 2009;158:e27‐e34. doi:10.1016/j.ahj.2009.06.006
Mizukoshi K, Suzuki K, Yoneyama K, Kamijima R, Kou S, Takai M, et al. Early diastolic function during exertion influences exercise intolerance in patients with hypertrophic cardiomyopathy. J Echocardiogr 2013;11:9‐17. doi:10.1007/s12574‐012‐0150‐0
Efthimiadis GK, Giannakoulas G, Parcharidou DG, Pagourelias ED, Kouidi EJ, Spanos G, et al. Chronotropic incompetence and its relation to exercise intolerance in hypertrophic cardiomyopathy. Int J Cardiol 2011;153:179‐184. doi:10.1016/j.ijcard.2010.08.026
Achim A, Serban AM, Mot SDC, Leibundgut G, Marc M, Sigwart U. Alcohol septal ablation in hypertrophic cardiomyopathy: for which patients? ESC Heart Fail 2023;10:1570‐1579. doi:10.1002/ehf2.14272
Lancellotti P, Pellikka PA, Budts W, Chaudhry FA, Donal E, Dulgheru R, et al. The clinical use of stress echocardiography in non‐ischaemic heart disease: recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging 2016;17:1191‐1229. doi:10.1093/ehjci/jew190
Guazzi M, Arena R, Halle M, Piepoli MF, Myers J, Lavie CJ. 2016 focused update: clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Eur Heart J 2018;39:1144‐1161. doi:10.1093/eurheartj/ehw180
Authors/Task Force members, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J 2014;35:2733‐2779. doi:10.1093/eurheartj/ehu284
Shimiaie J, Sherez J, Aviram G, Megidish R, Viskin S, Halkin A, et al. Determinants of effort intolerance in patients with heart failure: combined echocardiography and cardiopulmonary stress protocol. JACC: Heart Fail 2015;3:803‐814. doi:10.1016/j.jchf.2015.05.010
Guazzi M, Adams V, Conraads V, Halle M, Mezzani A, Vanhees L, et al. EACPR/AHA scientific statement. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Circulation 2012;126:2261‐2274. doi:10.1161/CIR.0b013e31826fb946
Khan MN, Pothier CE, Lauer MS. Chronotropic incompetence as a predictor of death among patients with normal electrograms taking beta blockers (metoprolol or atenolol). Am J Cardiol 2005;96:1328‐1333. doi:10.1016/j.amjcard.2005.06.082
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440‐1463.
Haykowsky MJ, Brubaker PH, Stewart KP, Morgan TM, Eggebeen J, Kitzman DW. Effect of endurance training on the determinants of peak exercise oxygen consumption in elderly patients with stable compensated heart failure and preserved ejection fraction. J Am Coll Cardiol 2012;60:120‐128.
Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, et al. Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state‐of‐the‐art review. J Am Coll Cardiol 2022;79:372‐389. doi:10.1016/j.jacc.2021.12.002
Maron MS, Olivotto I, Maron BJ, Prasad SK, Cecchi F, Udelson JE, et al. The case for myocardial ischemia in hypertrophic cardiomyopathy. J Am Coll Cardiol 2009;54:866‐875.
Achim A, Savaria BU, Buja LM. Commentary on the enigma of small vessel disease in hypertrophic cardiomyopathy: is invasive assessment of microvascular resistance a novel independent predictor of prognosis? Cardiovasc Pathol 2022;60:107448. doi:10.1016/j.carpath.2022.107448
Kurt M, Wang J, Torre‐Amione G, Nagueh SF. Left atrial function in diastolic heart failure. Circ Cardiovasc Imaging 2009;2:10‐15. doi:10.1161/CIRCIMAGING.108.813071
Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, et al. Prognostic value of quantitative contrast‐enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 2014;130:484‐495. doi:10.1161/CIRCULATIONAHA.113.007094
Masri A, Pierson LM, Smedira NG, Agarwal S, Lytle BW, Naji P, et al. Predictors of long‐term outcomes in patients with hypertrophic cardiomyopathy undergoing cardiopulmonary stress testing and echocardiography. Am Heart J 2015;169:684‐692.e1. doi:10.1016/j.ahj.2015.02.006
Peteiro J, Bouzas‐Mosquera A, Fernandez X, Monserrat L, Pazos P, Estevez‐Loureiro R, et al. Prognostic value of exercise echocardiography in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2012;25:182‐189.
Jones S, Elliott PM, Sharma S, McKenna WJ, Whipp BJ. Cardiopulmonary responses to exercise in patients with hypertrophic cardiomyopathy. Heart 1998;80:60‐67. doi:10.1136/hrt.80.1.60
Caforio AL, Rossi B, Risaliti R, Siciliano G, Marchetti A, Angelini C, et al. Type 1 fiber abnormalities in skeletal muscle of patients with hypertrophic and dilated cardiomyopathy: evidence of subclinical myogenic myopathy. J Am Coll Cardiol 1989;14:1464‐1473. doi:10.1016/0735‐1097(89)90383‐5
Snir AW, Connelly KA, Goodman JM, Dorian D, Dorian P. Exercise in hypertrophic cardiomyopathy: restrict or rethink. Am J Physiol‐Heart Circ Physiol 2021;320:H2101‐H2111. doi:10.1152/ajpheart.00850.2020
Guazzi M, Adams V, Conraads V, Halle M, Mezzani A, Vanhees L, et al. EACPR/AHA joint scientific statement. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Eur Heart J 2012;33:2917‐2927.
Dumont CA, Monserrat L, Peteiro J, Soler R, Rodriguez E, Bouzas A, et al. Relation of left ventricular chamber stiffness at rest to exercise capacity in hypertrophic cardiomyopathy. Am J Cardiol 2007;99:1454‐1457. doi:10.1016/j.amjcard.2006.12.077
Lafitte S, Reant P, Touche C, Pillois X, Dijos M, Arsac F, et al. Paradoxical response to exercise in asymptomatic hypertrophic cardiomyopathy: a new description of outflow tract obstruction dynamics. J Am Coll Cardiol 2013;62:842‐850.
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451‐1461. doi:10.1056/NEJMoa2107038
Solomon SD, McMurray JJV, Claggett B, De Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022;387:1089‐1098. doi:10.1056/NEJMoa2206286
Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018;378:417‐427. doi:10.1056/NEJMoa1707855
Sohns C, Fox H, Marrouche NF, Crijns HJGM, Costard‐Jaeckle A, Bergau L, et al. Catheter ablation in end‐stage heart failure with atrial fibrillation. N Engl J Med 2023;389:1380‐1389. doi:10.1056/NEJMoa2306037